A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Imovax Pharmacology, Pharmacokinetics, Studies, Metabolism - Rabies Vaccine
Imovax Pharmacology, Pharmacokinetics, Studies, Metabolism - Rabies Vaccine
CLINICAL PHARMACOLOGY
Studies in Europe (1-6) and in the United States (7,8) to investigate
the efficacy and safety
of low dose intradermal
vaccination schedules
have shown that satisfactory levels of antibody
were produced in all subjects with two or more inoculations.
Studies in the United States (7,8,9) using three doses of Mérieux’s
Rabies Vaccine demonstrated adequate rabies
antibody titers in
100% of persons receiving intradermal
injections. The geometric mean
titer in these subiects
49 days after immunization
was approximately 7.5 to 8.9 I. U. compared with 12.9 to 13.8 I.
U. in controls receiving 1.0 ml
of vaccine intramuscularly (7).
The definition of
a minimally acceptable antibody
titer varies both among
laboratories and according to the purposes for which immunization
is given. The Centers for Disease Control (CDC) currently specifies
complete virus neutralization
at a 1:5 serum dilution
in the rapid fluorescent
focus inhibition test (RFFIT)
as an acceptable response
to pre-exposure immunization. After studies of post-exposure immunization,
the World Health Organization (WHO) specifies a titer
of 0.5 I. U. as an acceptable response.
top
